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Abstract  The  incidence  of  neuroendocrine  tumors  of  the  rectum  has  been  increasing  in  the  last
decades, partly  due  to  improved  investigation.  They  are  mostly  well-differentiated  small  tumors
with a  rather  good  overall  prognosis.  In  the  last  few  years,  some  aspects  of  neuroendocrine
tumors  have  been  evolving.  In  2010,  the  World  Health  Organization  proposed  a  new  classiﬁca-
tion, indicating  that  these  tumors,  as  a  category,  should  be  considered  malignant.  Afterwards
the European  Neuroendocrine  Tumor  Society  published  their  guidelines  for  the  management  of
colorectal  neoplasms.  Treatment  algorithm  is  mainly  based  on  tumor  size  and  grading  and,  in
general, well-differentiated  rectal  tumors  <2  cm  can  be  endoscopically  resected.  Endorectal
ultrasound plays  a  particularly  important  role  by  accurately  assessing  tumor  size  and  depth  of
invasion prior  to  resection.  There  are  no  speciﬁc  recommendations  on  the  optimal  endoscopic
resection  method,  but  data  from  recent  studies  suggests  that  modiﬁed  endoscopic  mucosal
resection  techniques  and  endoscopic  submucosal  dissection  have  superior  complete  resection
rates.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier  España,  S.L.U.  This  is
an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Tumores  Neuroendócrinos  do  Reto:  Características  Principais  e  Orientac¸ão  Clínica
Resumo  A  incidência  dos  tumores  neuroendócrinos  do  reto  tem  vindo  a  aumentar  nas  últimas
Neoplasias  do  Reto décadas,  em  parte  devido  a  uma  maior  investigac¸ão.  Estes  são  sobretudo  tumores  pequenos,
bem diferenciados  e  com  um  bom  prognóstico  global.  Nos  últimos  anos,  alguns  aspetos  rela-
cionados com  os  tumores  neuroendócrinos  têm  vindo  a  evoluir.  Em  2010,  a  Organizac¸ão  Mundial
 classiﬁcac¸ão,  sugerindo  que  estes  tumores,  enquanto  categoria,
alignos.  Posteriormente,  a  Sociedade  Europeia  de  Tumores  Neu-
uas  recomendac¸ões  para  a  orientac¸ão  das  neoplasias  colorretais.da Saúde  propôs  uma  nova
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O  algoritmo  de  tratamento  baseia-se  principalmente  no  tamanho  do  tumor  e  no  grau  tumoral
e, em  geral,  tumores  do  reto  bem  diferenciados,  inferiores  a  2  cm,  podem  ser  submetidos  a
ressec¸ão endoscópica.  A  ecograﬁa  endorretal  desempenha  um  papel  particularmente  impor-
tante ao  permitir  avaliar  com  precisão  o  tamanho  do  tumor  e  profundidade  de  invasão  antes
da ressec¸ão.  Não  existem  recomendac¸ões  especíﬁcas  sobre  o  método  de  ressec¸ão  endoscópica
ideal, no  entanto,  dados  de  estudos  recentes  sugerem  que  técnicas  modiﬁcadas  de  mucosecto-
mia e  dissec¸ão  da  submucosa  têm  taxas  superiores  de  ressec¸ão  completa.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.U.  Este  é
um artigo  Open  Access  sob  a  licença  de  CC  BY-NC-ND  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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c. Introduction
euroendocrine  neoplasms  in  the  digestive  system  are
enerically  referred  as  gastroenteropancreatic  tumors  (GEP-
ETs).  GEP-NETs  constitute  a  heterogeneous  group  of  tumors
rising  from  neuroendocrine  cells  of  the  embryological
ut  that  share  a  common  phenotype  with  immunoreactiv-
ty  for  the  neuroendocrine  markers,  chromogranin  A  and
ynaptophysin1.  Some  tumors  produce  a  variety  of  hormones
nd  amines  leading  to  distinct  clinical  syndromes  (function-
ng  tumors).2
These  neoplasms  used  to  be  called  ‘‘carcinoids’’,  the
riginal  term  used  by  Oberndorfer,  in  1907,  to  describe
umors  that  appeared  to  have  a  more  benign  behavior  than
arcinomas.  However  this  term  has  been  progressively  aban-
oned  in  favor  of  neuroendocrine  neoplasms.3
. Classiﬁcation
revious  classiﬁcation  of  GEP-NETs  divided  tumors  based  on
mbryonic  derivation,  in  those  of  the  foregut  (respiratory
ract,  upper  gastrointestinal  tract  and  pancreas),  midgut
small  bowel  and  right  colon)  and  hindgut  (the  remaining
wo  thirds  of  colon  and  rectum).  However,  even  within  this
lassiﬁcation  there  is  marked  heterogeneity  and  differences
n  behavior  of  tumors  and  thus  classiﬁcation  is  better  based
n  anatomic  location  and  grading  of  the  tumor.3
In  2010,  the  World  Health  Organization  (WHO)  deﬁned  a
lassiﬁcation  for  neuroendocrine  neoplasms  of  the  digestive
ystem,  according  to  which  all  tumors  are  considered  malig-
ant  with  the  potential  to  metastasize.  Tumor  grade  is  based
n  mitotic  count  and  on  proliferation  (Ki-67  index)  and  the
hree  levels  deﬁned  are  described  in  Table  1.
When  grades  assessed  by  mitotic  count  and  Ki-67  differ,
he  higher  grade  is  assumed.  This  new  classiﬁcation  recog-
izes  the  following  categories:  neuroendocrine  tumor  (NET),
Table  1  Tumor  grade  according  to  mitotic  count  and
proliferation.
WHO  grade  Mitotic  count  (10  HPFa)  Ki-67  index
G1  <2  ≤2%
G2  2--20  3--20%
G3 >20  >20%
a Per 10 high-power ﬁelds.
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seuroendocrine  carcinoma  (NEC)  and  mixed  adenoneuroen-
ocrine  carcinoma.
NETs  are  well-differentiated  neuroendocrine  neoplasms,
ith  low  cellular  atypia  and  proliferative  activity  and
omprises  grade  G1  or  G2  tumors.  NECs  are  a  poorly  differen-
iated  neuroendocrine  neoplasm,  showing  marked  cellular
typia  and  high  proliferative  activity.  NECs  are  grade  G3
umors  and  two  categories  are  recognized:  large  cell  NEC
nd  small  cell  NEC.4,5
Jernman  et  al6 demonstrated  that  this  new  WHO  classi-
cation  predicted  the  metastatic  potentional  of  rectal  NETs
etter  than  the  previous  2000  classiﬁcation,  since  G1  NETs
ad  an  indolent  clinical  course  and  G2  NETs  often  metasta-
ize.  Yamaguchi  et  al7 also  concluded  that  the  classiﬁcation
f  gastrointestinal  NETs  into  G1  and  G2  based  on  Ki-67  index
as  appropriated  to  predict  metastases  and  recurrences;
or  Salama  et  al8 Ki-67  appears  as  a  reliable  and  repro-
ucible  marker  for  the  grading  of  NETs  and  more  superior
han  mitotic  rate.
The  American  Joint  Cancer  Commission  published,  in
010,  a  tumor--node--metastasis  (TNM)  classiﬁcation  system
or  colorectal  NETs  similar  to  the  one  previous  proposed  by
he  European  Neuroendocrine  Tumor  Society  (Table  2).9
In  order  to  assess  the  relevance  of  the  TNM  classiﬁca-
ion  system,  Jann  et  al10 conducted  a  retrospective  study
ith  midgut  and  hindgut  NETs  that  conﬁrmed  the  prognostic
elevance  and  applicability  of  the  classiﬁcation.
In  2012,  the  European  Neuroendocrine  Tumor  Society
ENETS)  released  guidelines  for  the  management  of  patients
ith  colorectal  neuroendocrine  neoplasms,  to  reﬂect  the
ew  relevant  data  on  this  matter,  including  the  WHO
lassiﬁcation.5
. Epidemiology
ata  from  the  Surveillance,  Epidemiology  and  End  Results
SEER)  suggests  that  the  incidence  of  rectal  NETs  have  been
ncreasing  over  the  last  decades;  rectal  NETs  represented
9%  of  all  GEP-NETs  in  the  latest  report,  establishing  the
ectum  as  the  most  common  location,  slightly  above  the
mall  intestine.11 In  Europe,  as  indicated  by  an  English12
nd  an  Austrian13 studies,  the  rectum  was  the  ﬁfth  and
ourth  most  common  location  with  a  frequency  of  8%  and
4%,  respectively.  In  Asia,  rectal  NETs  take  on  special
elevance,  representing  56%  of  all  GEP-NETs  in  Ito  et  al14
tudy.  In  Modlin  et  al15 report,  rectal  NETs  also  appear  to
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Table  2  American  Joint  Cancer  Commission  2010  TNM
classiﬁcation.
T  (primary  tumor)
Tx  Primary  tumor  cannot  be  assessed
T0 No  evidence  of  primary  tumor
T1 Tumor  invades  lamina  propria  or  submucosa  and
size ≤2  cm
T1a  Tumor  size  <1  cm  in  greatest  dimension
T1b  Tumor  size  1--2  cm  in  greatest  dimension
T2  Tumor  invades  muscularis  propria  or  size  >2  cm
with  invasion  of  lamina  propria  or  submucosa
T3 Tumor  invades  through  muscular  propria  into
subserosa  or  into  nonperitonealized  pericolic  or
perirectal  tissue
T4  Tumor  invades  peritoneum  or  other  organs
N (Regional  Lymph  nodes)
Nx  Regional  lymph  nodes  cannot  be  assessed
N1 No  regional  lymph  node  metastases
N2 Regional  lymph  node  metastases
M (Distant  metastases)
M0  No  distant  metastases
M1  Distant  metastases
Stage
I T1N0M0
IIA  T2N0M0
IIB  T3N0M0
IIIA  T4N0M0
a
s
T
a
m
m
c
d
>
r
p
5
5
R
t
i
(
a
b
i
c
5
R
dIIIB  AnyTN1M0
IV  AnyTAnyNM1
be  over-represented  among  the  Asian  populations  within
the  United  States.  These  data  suggests  that  there  are  likely
genetic  pre-disposing  factors,  although  some  differences
may  also  be  attributable  to  higher  colonoscopy  screening
rates  and  better  reporting  of  polyps  removed  at  endoscopy.3
Rectal  NETs  may  have  a  slight  male  preponderance16,17
and  the  diagnosis  is  usually  made  in  the  sixth  decade  of
life.16--18
4. Clinical characteristics, prognosis
Most  patients  are  asymptomatic  and  diagnosis  is  made
upon  routine  lower  endoscopy  or  for  investigation  of
unrelated  symptoms.  In  symptomatic  patients,  the  most  fre-
quent  symptoms  are  rectal  bleeding,  pain,  constipation  and
tenesmus.3,16 Carcinoid  syndrome  is  very  rare  as  the  tumors
themselves  rarely  produce  serotonin.5
The  majority  of  rectal  NETs  are  small  size  lesions;  in
a  recent  systematic  review  79%  of  tumors  were  less  than
1  cm  and  only  5%  were  greater  than  2  cm.19 Kasuga  et  al20
reported  a  mean  tumor  size  of  7.1  mm  in  their  series.  Most
lesions  are  found  in  the  midrectum  as  suggested  by  Kim  et
al21 study,  in  which  74.8%  of  tumors  were  found  between  5
and  9.9  cm  of  the  anal  verge.Most  rectal  NETs  (89%)  are  limited  to  the  submucosa
layer20 and  are  low  grade  tumors;  Weinstock  et  al22 reported
that  G1  tumors  accounted  for  88.1,  G2  for  8.2  and  G3  for
3.5%  of  rectal  neoplasms  in  their  series.
m
t
f
iFigure  1  Submucosal  tumor  in  the  middle  rectum.
Lymph  node  and  distant  metastasis  are  found  in  about  8%
nd  4%  of  patients,  respectively.20
Rectal  NETs  have  a  good  overall  prognosis  with  a  5-year
urvival  rate  of  75.2--88.3%.15
Disease  stage  is  the  main  prognostic  factor  of  rectal  NETs.
he  5-year  overall  survival  rates  reported  are  94--100,  54--74
nd  15--37%  for  patients  with  localized,  nodal  positive  and
etastatic  rectal  NETs,  respectively.23
Risk  factors  for  metastatic  disease  include  tumor  size,
uscularis  propria  invasion,  proliferation  index,  lymphovas-
ular  and  perineural  invasion.5,20,23 Yoon  et  al.16 described
istant  metastasis  rates  for  tumors  ≤1  cm,  >1  to  ≤2  cm,  and
2  cm  of  1.7,  15  and  50%,  respectively.  Weinstock  et  al22
eported  5-years  survival  rates  of  87.7,  47.6  and  33.3%  for
atients  with  G1,  G2  e  G3  tumors,  respectively.
.  Diagnosis and staging
.1.  Colonoscopy
ectal  NETs  appear  usually  as  small,  sessile,  submucosal
umors  covered  with  yellow  discolored  mucosa.19 Atyp-
cal  endoscopic  features  such  as  unusual  tumor  shape
semipedunculated  and  ulcerofungating),  color  (hyperemia)
nd  surface  change  (depression,  erosion,  and  ulceration)  can
e  associated  with  metastasis.21
A  full  colonoscopy  is  recommended  to  exclude  concom-
tant  colonic  disease  and  the  possibility  of  synchronous
arcinoma5 (Figs.  1  and  2).
.2.  Rectal  ultrasound
ectal  ultrasound  (RUS)  can  accurately  assess  tumor  size,
epth  of  invasion  and  presence  of  pararectal  lymph  node
etastases,  which  is  particularly  important  to  determine
he  adequate  treatment  modality.5 Kobayashi  et  al  per-
ormed  ultrasonographic  evaluation  with  echocolonoscopes
n  21  lesions  and  ultrasonic  probes  in  32  lesions.  Rectal
216  Â.  Rodrigues  et  al.
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aFigure  2  Submucosal  tumor  with  yellow  discolored  mucosa.
ETs  appeared  as  well-demarcated,  homogenous,  isoechoic
r  hypoechoic  lesions  and  the  depth  of  invasion  was  cor-
ectly  identiﬁed  in  all  lesions  (submucosal  in  49/52  lesions).
US  could  accurately  diagnose  the  invasion  depth  of  lesions
s  small  as  2  mm  in  diameter.24 High  frequency  ultrasound
robes  proved  to  be  especially  useful  in  assessing  invasion
f  small  lesions  limited  to  the  mucosa  or  submucosa25 and
herefore  can  be  particularly  adequate  for  evaluating  the
epth  of  invasion  in  neuroendocrine  rectal  tumors.  Another
wo  studies  found  an  accuracy  of  91  and  100%  for  determi-
ation  of  tumor  invasion  with  RUS.26,27According  to  ENETS  recommendation  RUS  should  be  per-
ormed  prior  to  treatment  to  determine  tumor  invasion5
Figs.  3  and  4).
Figure  3  Hypoechoic  lesion  on  the  muscularis  mucosa  layer.
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tFigure  4  Hypoechoic  lesion  on  the  submucosal  layer.
.3.  Computed  tomography  and  magnetic
esonance
n  rectal  NETs,  the  role  of  computed  tomography  (CT)  is
ot  to  detect  the  primary  tumor  nor  to  appreciate  its  inva-
ion  of  the  rectal  wall,  but  to  detect  regional  and  distant
etastases.  CT  has  a  reported  mean  detection  rate  for
iver  metastasis  in  neuroendocrine  tumors  of  81%.  The  CT
ppearance  of  NET  lymph  node  metastases  is  similar  to  those
rom  other  malignant  tumors,  although  a  marked  contrast
nhancement  is  frequent.2
Magnetic  resonance  imaging  (MRI)  is  superior  for  deter-
ining  liver  metastases  and  can  be  used  where  there
s  uncertainty  over  the  nature  of  lesions  identiﬁed  on
T.3,5
The  ENETS  consensus  recommend  CT/MRI  for  patients
ith  tumors  >10  mm  in  size  and  when  residual  and
etastatic  disease  is  suspected.5 In  the  NANETS  guidelines
t  is  stated  that  for  tumors  smaller  than  2 cm  and  conﬁned
o  the  mucosa  or  submucosa,  these  studies  are  not  routinely
ecommended.9
.4.  Scintigraphic  scanning  (Octreoscan)
adiolabelled  somatostatin  analogs  are  used  to  detect
omatostatin  receptor  positive  tissue.  The  detection  of
rimary  tumor  in  the  rectum  NETs  can  be  difﬁcult
ecause  of  greater  background  activity.  In  addition,  some
umors  may  not  express  somatostatin  receptors,  par-
icularly  higher  grade  NETS,  and  so  the  presence  of
etastatic  disease  is  better  evaluated  by  other  methods
uch  as  CT.  In  the  presence  of  metastatic  disease,  this
ethod  can  be  useful  to  determine  somatostatin  recep-
or  expression  which  may  have  impact  in  selecting  some
herapies.3,5
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5.5.  Positive  emitron  tomography  (PET)
Nowadays,  Octreoscan  can  be  replaced  by  Gallium-68  DOTA
octreotide  PET,  which  has  higher  sensitivity  and  speciﬁcity.1
However  this  method  is  less  available.
FDG  (18F  6-ﬂuordopamine)  PET  is  helpful  for  staging
high  grade/poorly  differentiated  tumors  that  do  not  express
somatostatin  receptors.3 Octeoscan  and  PET  should  be  used
for  staging  if  residual  or  metastatic  disease  is  suspected.5
5.6.  Biochemical  markers
Serum  Chromagranin  A  is  a  useful  marker  in  many  neu-
roendocrine  tumors  but  of  limited  use  in  non-metastatic
rectal  NETS.3 It  can  be  useful  for  monitoring  patients
with  metastatic  disease  or  for  surveillance  in  patients
with  resected  stage  II  and  III  tumors.9 Urinary  5-
hydroxyindoleacetic  acid  is  of  little  use  as  few  tumors
produce  serotonin.3
5.7.  Treatment
Tumor  size  is  the  most  important  predictor  of  tumor
behavior,  and  although  other  characteristics  are  taken  into
account,  this  is  the  main  determinant  in  selecting  the  treat-
ment  option.5,9 Lesions  <1  cm  have  a  low  risk  of  lymph  node
and  distant  metastasis.  The  outcome  of  intermediate-sized
(between  1  and  2  cm)  lesions  is  less  clear  but  they  have  a
higher  risk  of  metastasis  and  a  poorer  prognosis  compared
to  those  <1  cm.5,23 Park  et  al26 found  that  the  tumor  size
that  constituted  a  risk  factor  for  metastasis  was  >  1.4  cm.
Nevertheless,  the  ENETs  recommendations  suggest  that  rec-
tal  NETs  up  to  2  cm  with  low  mitotic  rate  and  no  muscularis
propria  invasion  or  lymph  node  involvement  can  mostly  be
endoscopically  ressected.5 For  Mestier  et  al,  only  tumors
<15  mm  should  be  treated  endoscopically.23 Among  tumors
<1  cm,  G2  grade  cannot  always  be  considered  as  a  high
risk  factor  taking  into  account  the  broad  heterogeneity
(mitotic  count  2--20  and  Ki-67  index  3--20%).  The  ‘‘low’’  G2
tumors,  may  behave  like  G1  tumors  and  could  theoretically
be  treated  in  the  same  manner.23
Based  on  endoscopic  and  ultrasonographic  characteris-
tics,  local  excision  is  often  performed  without  biopsy  and
the  subsequent  management  will  depend  on  margin  sta-
tus  and  risk  factors  for  local  and  distant  recurrence.5,23 A
study  found  that  performing  biopsy  before  endoscopic  exci-
sion  was  associated  with  incomplete  endoscopic  resection.
The  authors  pointed  out  that  the  lesion  may  be  ﬂat-
tened  and  margins  blurred  after  biopsy  and  snaring  and
targeting  the  lesion  afterwards  may  be  more  difﬁcult
and  also  tissue  ﬁbrosis  after  biopsy  may  also  disturb
ressection.28
Various  endoscopic  resection  techniques  have  been
applied  to  rectal  NETs,  including  conventional  polypectomy,
endoscopic  mucosal  resection  (EMR)  and  endoscopic  sub-
mucosal  dissection  (ESD).  Other  techniques,  derived  from
conventional  EMR  have  been  used  and  include  EMR  with  cap
aspiration  (EMR-C),  endoscopic  submucosal  resection  using
a  ligation  device  (ESMR-L)  and  EMR  using  a  dual-channel
endoscope  (EMR-D).  There  are  no  speciﬁc  recommendations
for  selecting  the  optimal  endoscopic  treatment,  however
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t  is  important  to  attain  a complete  tumor  resection.
nsuccessfully  resected  lesions  will  need  follow-up  or
dditional  treatment.23
With  conventional  polypectomy,  it  is  difﬁcult  to  achieve
 tumor-free  resection  margin,  as  NETs  generally  pene-
rate  the  muscularis  mucosa  into  the  submucosal  layer.  Son
t  al.  reported  a pathologically  complete  resection  rate  of
nly  18.5%  after  polipectomy.29 Data  regarding  complete
esection  rates  with  conventional  EMR  are  highly  variable;
n  three  different  studies  these  rates  were  42.9,  64.3  and
7.4%.29--31
EMR-C  and  ESMR-L  allow  the  creation  of  a  pseudopedi-
le  prior  to  resection  generally  obtaining  a  deeper  excision
omparing  with  EMR  and  polypectomy.32 In  EMR-D  the  lesion
an  be  pulled  into  the  snare  using  a  grasping  forceps  before
losing  the  snare  and  proceed  with  the  resection.33 Two  stud-
es  reported  a  complete  resection  of  100  and  93.9%  with
SMR-L  compared  to  77.4  and  65.5%  with  conventional  EMR,
espectively.30,34 Son  et  al29 reported  tumor-free  margins  in
1.7%  of  53  patients  treated  with  EMR-C  compared  to  42.9%
reated  with  EMR.  In  Jeon  et  al35 study  EMR-C  was  performed
s  a  salvage  treatment  in  31  patients  that  failed  en  bloc
xcision  after  primary  EMR  or  polypectomy,  achieving  clear
esection  margins  in  all  cases.  Two  studies  reported  com-
lete  resection  rates  of  74.1%  and  84.6%  for  EMR-D.34,36 In
he  ﬁrst,  the  resection  rate  of  this  method  was  similar  to
onventional  EMR.  A concern  with  this  technique  is  that  the
ucosa  can  be  torn  before  the  tumor  is  adequately  elevated
ith  the  grasping  forceps.37
ESD  is  a  good  therapeutic  option,  but  at  the  same  time  is
 more  challenging  procedure,  because  of  its  technical  dif-
culty,  the  need  of  special  devices  and  of  an  experienced
ndoscopist.  Lee  et  al31 found  a  pathological  complete
esection  rate  of  82.6%  for  ESD  compared  with  64.3%  for  EMR
roup.  Another  two  studies  reported  a  complete  resection
ate  of  97.7  and  80.6%  for  ESD,  and  on  both  these  rates
ere  similar  to  those  achieved  with  ESMR-L.30,38 Choi  et  al38
uggests  that  ESMR-L  may  be  considered  the  treatment  of
hoice  for  rectal  NETs  based  on  comparable  histologically
omplete  resection  rates  and  given  the  advantages  of  easier
nd  shorter  procedure  time.  Kim  et  al30 did  not  ﬁnd  an  infe-
ior  procedure  time  for  ESMR-L  compared  to  ESD  but  several
actors  could  explain  these  ﬁnding:  the  deﬁnition  of  proce-
ure  time  did  not  include  the  time  during  post-procedure
leeding  control  which  can  be  considerable  during  ESD;
SD  in  the  rectum  may  be  easier  than  other  parts  of  the
olon  and  ﬁnally  ESD  was  performed  by  a highly  trained
ndoscopist.
A  recent  meta-analysis  reported  a  higher  rate  of  patho-
ogical  complete  resection  among  patients  treated  with  the
odiﬁed  EMR  techniques  (EMR-M)  or  ESD  than  among  those
reated  with  conventional  EMR  (OR  0.42),  while  there  was
o  signiﬁcant  difference  between  the  ﬁrst  two  groups  (OR
.19).  The  procedure  time  for  ESD  was  longer  than  those
or  EMR  or  EMR-M  groups  and  it  was  insigniﬁcant  between
MR  and  EMR-M.  There  were  not  detected  signiﬁcant  dif-
erences  in  complications  or  recurrence  between  the  three
roups.39After  excision,  the  resection  area  must  be  tattooed  in
rder  to  facilitate  the  lesion  site  location  in  case  the  positive
argins  are  identiﬁed  and  further  resection  or  vigilance  is
equired.9
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Suspected rectal NET at
colonoscopy
RUS
1-2 cm<1 cm >2 cm
No metastasisMuscularis propriainvasion, lymph node
involvement, G3
Anterior resection or
abdominoperineal
exstirpation
Anterior resection or
abdominoperineal
exstirpation
No muscularis propria
invasion, no lymph node
involvement, G1-G2
Muscularis propria
invasion, G2-G3
Endoscopic resection
(preferably modified EMR
or ESD
Transanal excision
*adapted from ENETs consensus guidelines5 and Mestier et al review23
Transanal excision
Consider endoscopic
resection (preferably
modiified EMR or ESD) for
G1 tumors, mainly <15mm
No muscularis propria
invasion, G1-G2
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Although  a  negative  resection  margin  is  desirable,  its  pos-
tivity  is  not  a  completely  satisfactory  predictor  of  remnant
umor,  relapse  or  metastases.  By  cauterization  during  endo-
copic  resection,  the  destruction  of  adjacent  tumor  cells  can
terilize  the  resection  site.23 In  a  study  with  107  rectal  NETs
10  mm  treated  by  conventional  EMR  and  polypectomy,  15.9
nd  34.6%  had  positive  or  indeterminate  margins,  respec-
ively.  None  of  the  patients  experienced  local  or  distant
ecurrence  during  follow-up.40 In  another  study,  4  patients
ith  positive  resection  margins  underwent  transanal  endo-
copic  microsurgery  (TEM)  as  a  salvage  operation.  Posterior
athologic  assessment  only  showed  changes  due  to  scarring
ithout  a  remnant  tumor.30
Recommendations  for  incomplete  resection  with  endo-
copic  methods  consist  in  annual  follow  up  for  tumors  <1  cm
nd  G1  grading  and  transanal  excision  for  tumors  between
--2  cm  and  <1  cm  with  G2  and  G3  grading.5
In  addition  to  salvage  therapy  in  case  of  incomplete
esection  with  endoscopic  therapy,  transanal  excision  is
ommonly  performed  as  a  primary  therapy  for  intermediate-
ized  rectal  NETs  conﬁned  to  the  submucosa  or  for  patients
ith  smaller  tumors  invading  the  muscularis  propria  in
hom  lymph  node  metastasis  has  been  excluded.5,9 TEM  also
llows  full  thickness  excisions  and  several  advantages  over
onventional  transanal  excision  by  providing  an  improved
isualization,  exposure  and  access  to  higher  lesions  in  the
ectum.  Kinoshita  et  al.41 performed  27  TEM  procedures  (14
s  a  primary  excision  and  13  as  completion  surgery  after
ncomplete  endoscopic  resection)  attaining  clear  resection
argins  in  all  patients.
Rectal  tumors  >2  cm,  between  1  and  2  cm  with  muscu-
aris  invasion,  T3  or  T4  stage  and  G3  grading  and  tumors
ith  lymph  node  involvement  should  be  treated  similarly  to
denocarcinoma,  with  anterior  resection  and  total  mesorec-
al  excision  or  abdominoperineal  exstirpation  depending  on
istance  to  the  anal  verge.5
The  general  management  of  rectal  NETs  is  summarized  in
ig.  5.
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trithm  of  rectal  NETs.
.8.  Therapy  for  advanced  disease
ectal  NETs  are  mostly  localized  and  non-functioning
umors.  There  is  few  data  regarding  the  speciﬁc  treatment
f  metastatic  rectal  NETs  and  further  studies  are  neces-
ary.  Therapeutic  approaches  described  for  the  management
f  metastatic  disease  associated  with  neuroendocrine  neo-
lasms  include  surgical,  medical,  radiological  and  nuclear
edicine  strategies.42
Somatostatin  analogs  (SA)  are  the  standard  therapy  in
unctioning  NET  of  any  site,  as  they  control  symptoms  by
nhibiting  serotonin  and  other  vasoactive  substances  secre-
ion.  In  addition,  there  is  some  data  suggesting  that  SA  may
lso  have  an  antiproliferative  effect.  Therefore,  SA  may  be
sed  in  functioning  and  non-functioning  tumors,  particularly
n  cases  where  there  is  uptake  in  Octreoscan  or  Gallium-
8  DOTA  octreotide  PET.  Interferon  alfa  also  seems  to  have
n  anti-secretory  and  antiproliferative  effect  and  is  equally
ffective  in  functioning  and  non-functioning  tumors.9,42
Systemic  chemotherapy  is  recommended  for  G3  NEC  and
s  rarely  used  in  G1  and  G2  NETs  given  the  poor  results  in
hese  patients.5,42
In  peptide  receptor  radiotarget  therapy,  a  SA  is  linked  to  a
adioisotope  allowing  high  dose  radiotherapy  to  be  delivered
o  the  tumor  cells.  These  therapy  can  be  used  for  inoperable
etastatic  neuroendocrine  neoplasms  positive  for  somato-
tatin  receptors.3,5
Surgical  resection  of  liver  metastasis  has  been  used  either
n  a curative  intent  or  to  reduce  liver  tumor  burden  with
ebulking  resections.42
Various  ablative  and  locoregional  procedures  have  also
een  described  and  include  radiofrequency  ablation,  laser-
nduced  thermotherapy,  selective  hepatic  transcatheter
rterial  embolization  or  chemoembolization  and  selective
nternal  radiotherapy.  The  option  depends  on  the  local
xpertise  and  extension  and  location  of  liver  involvement.
hese  methods  can  be  used  as  sole  therapies  or  in  combina-
ion  with  surgery  or  medical  treatment.42
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6. Follow-up
Neuroendocrine  tumors  can  recur  even  many  years  after
resection,  but  there  is  little  consensus  about  the  best
surveillance  strategy.  The  ENETs  recommend3,9 follow-up  for
10  years5 and  the  NANETs  for  7  years.9
ENETs  recommendations  suggests  that  tumors  <1  cm,
G1--G2  grading,  with  no  muscularis  propria  and  lymph  node
involvement  completely  resected  do  not  require  regular
follow-up.  In  tumors  <1  cm  with  G3  grading  and  in  tumors
between  1  and  2  cm,  follow-up  may  be  performed  on  annual
basis.  Tumors  >2  cm  always  require  follow  up  on  an  annual
basis  for  G1--G2  tumors  and  on  every  4--6  months  in  the  ﬁrst
year  and  ﬁnally  at  least  annualy,  for  G3  tumors.  Although
there  is  not  a  speciﬁc  protocol  for  surveillance,  these
consensus  recommend  colonoscopy,  RUS,  MRI  for  rectal  eval-
uation,  TC  or  MRI  for  liver  metastasis  and  cromogranin  A.5
The  NANETs  do  not  recommend  routine  surveillance  for
stage  I  tumors;  for  stage  II  and  III  tumors  follow-up  may  be
performed  in  annually.9
7. Conclusions
Although  neuroendocrine  rectal  tumors  are  rare  they  are
increasing  in  incidence  and  recent  updates  have  been
made  regarding  the  classiﬁcation,  diagnostic  and  therapeu-
tic  approach.  Despite  a  relatively  indolent  behavior,  they
are  malignant  and  can  metastasize.  Most  reported  risk  fac-
tors  for  metastatic  disease  are  tumor  size  >1  cm,  muscularis
propria  invasion,  high  proliferation  index  and  lymphovas-
cular  invasion.  In  general,  low  risk  tumors  can  be  treated
by  endoscopic  resection  and  high  risk  tumors  need  surgi-
cal  excision.  Conventional  polypectomy  and  EMR  have  lower
complete  resection  rates  compared  to  modiﬁed  EMR  tech-
niques,  such  as  EMR-C,  ESMR-L  and  ESD.  The  prognosis  of
patients  with  metastatic  disease  is  poor  and  data  on  the
speciﬁc  treatment  of  these  patients  is  scarce.
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